Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens

被引：33

作者：

Haab, Brian B. ^{[1
]}

Huang, Ying ^{[2
]}

Balasenthil, Seetharaman ^{[3
]}

Partyka, Katie ^{[1
]}

Tang, Huiyuan ^{[1
]}

Anderson, Michelle ^{[4
]}

Allen, Peter ^{[5
]}

Sasson, Aaron ^{[6
]}

Zeh, Herbert ^{[7
]}

Kaul, Karen ^{[8
]}

Kletter, Doron ^{[9
]}

Ge, Shaokui ^{[2
]}

Bern, Marshall ^{[9
]}

Kwon, Richard ^{[4
]}

Blasutig, Ivan ^{[10
]}

Srivastava, Sudhir ^{[11
]}

Frazier, Marsha L. ^{[3
]}

Sen, Subrata ^{[3
]}

Hollingsworth, Michael A. ^{[6
]}

Rinaudo, Jo Ann

Killary, Ann M. ^{[3
,11
]}

Brand, Randall E. ^{[7
]}

机构：

[1] Van Andel Res Inst, Grand Rapids, MI USA

[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Michigan, Ann Arbor, MI 48109 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Univ Nebraska Med Ctr, Omaha, NE USA

[7] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA

[8] Northshore Univ Healthsyst, Evanston, IL USA

[9] Xerox Corp, Palo Alto Res Ctr, Palo Alto, CA 94304 USA

[10] Univ Hlth Network, Toronto, ON, Canada

[11] NCI, Rockville, MD USA

来源：

PLOS ONE | 2015年 / 10卷 / 10期

关键词：

MONOCLONAL-ANTIBODIES; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS; CA19-9; BIOMARKERS; ADENOCARCINOMA; IDENTIFICATION; CARCINOMA; DISEASES; MARKERS;

D O I：

10.1371/journal.pone.0139049

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The validation of candidate biomarkers often is hampered by the lack of a reliable means of assessing and comparing performance. We present here a reference set of serum and plasma samples to facilitate the validation of biomarkers for resectable pancreatic cancer. The reference set includes a large cohort of stage I-II pancreatic cancer patients, recruited from 5 different institutions, and relevant control groups. We characterized the performance of the current best serological biomarker for pancreatic cancer, CA 19-9, using plasma samples from the reference set to provide a benchmark for future biomarker studies and to further our knowledge of CA 19-9 in early-stage pancreatic cancer and the control groups. CA 19-9 distinguished pancreatic cancers from the healthy and chronic pancreatitis groups with an average sensitivity and specificity of 70-74%, similar to previous studies using all stages of pancreatic cancer. Chronic pancreatitis patients did not show CA 19-9 elevations, but patients with benign biliary obstruction had elevations nearly as high as the cancer patients. We gained additional information about the biomarker by comparing two distinct assays. The two CA 9-9 assays agreed well in overall performance but diverged in measurements of individual samples, potentially due to subtle differences in antibody specificity as revealed by glycan array analysis. Thus, the reference set promises be a valuable resource for biomarker validation and comparison, and the CA 19-9 data presented here will be useful for benchmarking and for exploring relationships to CA 19-9.

引用

页数：18